OVERVIEW

Targeting biomarkers is a key strategy for improving outcomes in metastatic colorectal cancer (CRC). Some of the most recent additions to the arsenal of targeted therapy are treatments targeting HER2, and practical guidance for their usage is needed. Christopher Lieu, MD, Associate Professor and Associate Director of Clinical Research at the University of Colorado Cancer Center, will provide expert perspectives on the following:

• Subsets of CRC in which HER2 testing is indicated
• The latest clinical trial data on emerging HER2-targeted therapies
• Practice guidelines on treatment combinations and sequencing for metastatic CRC
• Tips for optimizing the tolerability of novel targeted therapies for HER2-positive metastatic CRC
• Patient case studies to help inform your practice - And much more!
• For more information please visit the official event page.